MedTrace Logo

Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

NCT02425904 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-02-27

Study results available
· View outcomes & findings →

Summary

This research study is evaluating a drug called clofarabine as a possible treatment for Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.

Conditions

  • Langerhans Cell Histiocytosis

Interventions

DRUG

Clofarabine

second-generation purine nucleoside analog

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • St. Baldrick's Foundation

    collaborator OTHER

  • Cookies for Kids' Cancer

    collaborator OTHER

  • North American Consortium for Histiocytosis

    collaborator OTHER

  • Dana-Farber Cancer Institute

    lead OTHER

Principal Investigators

  • Barbara Degar, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2020-01-31
Completion
2026-07-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02425904 on ClinicalTrials.gov